title: Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property.
authors.forename: Sayaka
authors.initials: S
authors.lastname: Maeda
authors.forename: Takanori
authors.initials: T
authors.lastname: Matsui
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Takeuchi
authors.forename: Sho-ichi
authors.initials: S
authors.lastname: Yamagishi
mesh_terms: D017667:Adipocytes / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D052242:Adiponectin / Q000235:genetics*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D001383:Azetidinecarboxylic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002478:Cells, Cultured; D004095:Dihydropyridines / Q000494:pharmacology*; D015536:Down-Regulation / Q000187:drug effects; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D018384:Oxidative Stress / Q000187:drug effects; D012333:RNA, Messenger / Q000378:metabolism; D013777:Tetrazoles / Q000494:pharmacology*
chemical_list: D052242:Adiponectin; D047228:Angiotensin II Type 1 Receptor Blockers; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D017127:Glycation End Products, Advanced; D007093:Imidazoles; D012333:RNA, Messenger; D013777:Tetrazoles; D001383:Azetidinecarboxylic Acid; C437965:olmesartan; C061679:azelnidipine